Grünenthal, a science-based pharmaceutical company developing treatments for different pain conditions, announced that its U.S. subsidiary Averitas Pharma received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults.
QUTENZA® is a topical, non-systemic, non-opioid pain treatment delivered in the form of a patch and is the first and only treatment of its kind to deliver prescription strength capsaicin directly into the skin. Thereby, it can reversibly desensitize the TRPV1 receptor, which plays a critical role in pain signaling, and provide sustained relief that lasts for up to three months.
QUTENZA® 8% patch has been approved in the US for the management of neuropathic pain associated with postherpetic neuralgia since 2009.
Photo by Elle Hughes on Unsplash